BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28069746)

  • 1. Non-alcoholic fatty pancreas disease.
    Alempijevic T; Dragasevic S; Zec S; Popovic D; Milosavljevic T
    Postgrad Med J; 2017 Apr; 93(1098):226-230. PubMed ID: 28069746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Pancreas Disease.
    Shah N; Rocha JP; Bhutiani N; Endashaw O
    Nutr Clin Pract; 2019 Oct; 34 Suppl 1():S49-S56. PubMed ID: 31535735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease.
    Catanzaro R; Cuffari B; Italia A; Marotta F
    World J Gastroenterol; 2016 Sep; 22(34):7660-75. PubMed ID: 27678349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.
    Filippatos TD; Alexakis K; Mavrikaki V; Mikhailidis DP
    Dig Dis Sci; 2022 Jan; 67(1):26-41. PubMed ID: 33469809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review.
    Romana BS; Chela H; Dailey FE; Nassir F; Tahan V
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):547-554. PubMed ID: 29595117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat.
    Della Corte C; Mosca A; Majo F; Lucidi V; Panera N; Giglioni E; Monti L; Stronati L; Alisi A; Nobili V
    Clin Endocrinol (Oxf); 2015 Nov; 83(5):656-62. PubMed ID: 26201937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty pancreas disease: clinical impact.
    Blaho M; Dítě P; Kunovský L; Martínek A
    Vnitr Lek; 2018; 64(10):949-952. PubMed ID: 30590942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Pancreas Disease: Clinical Consequences.
    Dite P; Blaho M; Bojkova M; Jabandziev P; Kunovsky L
    Dig Dis; 2020; 38(2):143-149. PubMed ID: 31865317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of non-alcoholic fatty pancreas disease on glucose metabolism.
    Yu TY; Wang CY
    J Diabetes Investig; 2017 Nov; 8(6):735-747. PubMed ID: 28371475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
    ; Lonardo A; Bellentani S; Argo CK; Ballestri S; Byrne CD; Caldwell SH; Cortez-Pinto H; Grieco A; Machado MV; Miele L; Targher G
    Dig Liver Dis; 2015 Dec; 47(12):997-1006. PubMed ID: 26454786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty pancreas disease - practices for clinicians.
    Pinte L; Balaban DV; Băicuş C; Jinga M
    Rom J Intern Med; 2019 Sep; 57(3):209-219. PubMed ID: 30901317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis.
    Bi Y; Wang JL; Li ML; Zhou J; Sun XL
    Diabetes Metab Res Rev; 2019 Jul; 35(5):e3142. PubMed ID: 30767421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipid accumulation in the pancreas: clinical significance of NAFPD (non-alcoholic fatty pancreas disease)].
    Jermendy G
    Orv Hetil; 2022 Oct; 163(44):1735-1742. PubMed ID: 36309887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes: Does pancreatic fat really matter?
    Guglielmi V; Sbraccia P
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 28984071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Alcoholic Fatty Pancreas Disease: The Unsung Disease.
    Sevim BC; Chela H; Ertugrul H; Malik LS; Malik S; Basar O; Daglilar E; Samiullah S; Gaballah AH; Tahan V
    Endocr Metab Immune Disord Drug Targets; 2023; 23(4):485-493. PubMed ID: 36177623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
    Pár A; Pár G
    Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Implications of Fatty Pancreas: A Concise Review.
    Khoury T; Asombang AW; Berzin TM; Cohen J; Pleskow DK; Mizrahi M
    Dig Dis Sci; 2017 Oct; 62(10):2658-2667. PubMed ID: 28791556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular mechanisms between metabolic syndrome and breast cancer.
    Chen Y; Wen YY; Li ZR; Luo DL; Zhang XH
    Biochem Biophys Res Commun; 2016 Mar; 471(4):391-5. PubMed ID: 26891869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.